# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k072599   
B. Purpose for Submission: Clearance of new methodology (turbidimetric immunoassay) for previously cleared device (enzyme immunoassay)   
C. Measurand: Lipoprotein-Associated Phospholipase $\mathbf { A } _ { 2 } \left( \mathbf { L } { \mathsf { p } } { \mathsf { - P L A } } _ { 2 } \right)$   
D. Type of Test: Quantitative turbidimetric immunoassay   
E. Applicant: diaDexus, Inc.   
F. Proprietary and Established Names: PLAC® Test Reagent Kit PLAC® Test Calibrator Kit Lp-PLA2 Control Kit

# G. Regulatory Information:

1. Regulation section:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>NOE-test, system,immunoassay,lipoprotein-associatedphospholipase a2</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.5600</td><td rowspan=1 colspan=1>82 Immunology</td></tr><tr><td rowspan=1 colspan=1>JIT- calibrator, secondary</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 866.1150</td><td rowspan=1 colspan=1>75 Chemistry</td></tr><tr><td rowspan=1 colspan=1>JX- quality controlmaterial</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.1660</td><td rowspan=1 colspan=1>75 Chemistry</td></tr></table>

# H. Intended Use:

1. Intended use(s):

See indications for use below.

2. Indication(s) for use:

The PLAC® Test Reagent Kit is a turbidimetric immunoassay for the quantitative determination of $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ (lipoprotein-associated phospholipase $\mathbf { A } _ { 2 } ^ { \prime }$ ) in human plasma or serum on automated clinical chemistry analyzers, to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for coronary heart disease, and ischemic stroke associated with atherosclerosis.

The $\mathbf { P L A C } ^ { \mathbf { ( B ) } }$ Test Calibrator Kit is intended to establish points of reference that are used in the determination of values in the measurement of $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ by the PLAC® Test Reagent Kit.

The Lp- $\mathbf { \Delta } \mathbf { P } \mathbf { L A } _ { 2 }$ Control Kit is intended for use as a quality control tool to monitor the performance within the clinical range of the $\mathsf { \bar { P } L A \bar { C } } ^ { \mathbb { \bar { R } } }$ Test Reagent Kit, a turbidimetric immunoassay for the quantitative determination of Lp-PLA2.

3. Special conditions for use statement(s): For professional use only

4. Special instrument requirements: The PLAC Test was validated on the Roche Hitachi® 917.

# I. Device Description:

• The diaDexus $\mathrm { P L A C } ^ { \mathrm { \scriptscriptstyle ( B ) } }$ Test assay consists of separately packaged reagents, calibrators and controls for the measurement of $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ in serum or plasma. The $\mathrm { P L A C } ^ { \mathrm { \tiny { ( R ) } } }$ Test Reagent Kit consists of two reagents. R1 is a tris-based buffer solution and R2 is a suspension of latex microparticles coated with mouse monoclonal antibodies specific to $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ (2C10 and 4B4).   
• The $\mathrm { P L A C } ^ { \mathrm { \textregistered } }$ Test Calibrator Kit is a five level set of $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ calibrators made with recombinant $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ in a protein stabilizing buffer and used to calibrate the PLAC assay. The $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ Control Kit is a two level set of $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ controls made with recombinant Lp- $\mathrm { \cdot P L A } _ { 2 }$ in a protein stabilizing buffer.

# J. Substantial Equivalence Information:

1. Predicate device name(s): diaDEXUS PLAC Test

2. Predicate K number(s): k062234, k050523 and k030477

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">PredicatePLAC Testk062234</td><td colspan="1" rowspan="1">CurrentDevice</td></tr><tr><td colspan="1" rowspan="1">IntendedUse</td><td colspan="1" rowspan="1">REAGENT KITThe diaDexus PLAC® Test is anenzyme immunoassay for thequantitative determination ofLp-PLA2 (lipoprotein-associatedphospholipase A2) in humanplasma and serum, to be used inconjunction with clinicalevaluation and patient riskassessment as an aid inpredicting risk for coronaryheart disease, and ischemicstroke associated withatherosclerosis.(Calibrators and controls wereincluded in kit.)</td><td colspan="1" rowspan="1">REAGENT KITThe PLAC® Test Reagent Kit is aturbidimetric immunoassay for thequantitative determination of Lp-PLA2 (lipoprotein-associatedphospholipase A2) in human plasmaor serum on automated clinicalchemistry analyzers, to be used inconjunction with clinical evaluationand patient risk assessment as an aidin predicting risk for coronary heartdisease, and ischemic strokeassociated with atherosclerosis.CALIBRATOR KITThe PLAC® Test Calibrator Kit isintended to establish points ofreference that are used in thedetermination of values in themeasurement of Lp-PLA2 by thePLAC® Test Reagent Kit.CONTROL KITThe Lp-PLA2 Control Kit isintended for use as a quality controltool to monitor the performancewithin the clinical range of thePLAC® Test Reagent Kit, aturbidimetric immunoassay for thequantitative determination of Lp-PLA2.</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Lp-PLA2</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">LaboratoryEnvironment</td><td colspan="1" rowspan="1">Professional laboratory</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Predicate PLAC® Test k062234</td><td colspan="1" rowspan="1">Current Device</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Serum, EDTA-plasma,heparin-plasma</td></tr><tr><td colspan="1" rowspan="1">ReagentComponents</td><td colspan="1" rowspan="1">Dual monoclonal antibodysandwich ELISA:•  anti-Lp-PLA2 mAb (2C10)coated strip wellsO   Wash BufferEnzyme Conjugate : anti-Lp-PLA2 mAb (4B4)-HRPTMB Substrate Solution•  Stop Solution</td><td colspan="1" rowspan="1">Two-reagent system:•R1: Tris-based buffersolutionR2: Suspension of anti-Lp-PLA2 (mAbs 2C10and 4B4) coated latexbeads</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Six calibrators made withrecombinant Lp-PLA2 in abuffered protein matrix (includedin ELISA kit)</td><td colspan="1" rowspan="1">Five calibrators made withrecombinant Lp-PLA2 in abuffered protein matrix (soldseparately)</td></tr><tr><td colspan="1" rowspan="1">CalibrationConc.</td><td colspan="1" rowspan="1">0, 50, 100, 250, 500, 1000 ng/mL</td><td colspan="1" rowspan="1">0, 50, 100, 250, 500 ng/mL</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Microplate Enzymeimmunoassay (ELISA)</td><td colspan="1" rowspan="1">Latex particle-enhancedturbidimetric immunoassay(particle agglutination)</td></tr><tr><td colspan="1" rowspan="1">DetectionMethod</td><td colspan="1" rowspan="1">Microplate spectrophotometerread at 450 nm</td><td colspan="1" rowspan="1">Automated clinicalchemistry analyzers read at570 nm</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

<table><tr><td rowspan=1 colspan=1>STANDARDS</td></tr><tr><td rowspan=1 colspan=1>Title and Reference Number</td></tr><tr><td rowspan=1 colspan=1>CLSI: Evaluation of the Linearity of Quantitative Measurement Procedures: AStatistical Approach; Approved Guideline (EP6-A).</td></tr><tr><td rowspan=1 colspan=1>CLSI: Interference Testing in Clinical Chemistry; Approved Guideline (EP 7-A)</td></tr><tr><td rowspan=1 colspan=1>CLSI: Method Comparison and Bias Estimation Using Patient Samples; ApprovedGuideline (EP09-A2)</td></tr><tr><td rowspan=1 colspan=1>CLSI: Evaluation of Precision Performance of Clinical Chemistry Devices;Approved Guideline (EP5-A)</td></tr></table>

# CLSI: Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline (EP9-A)

# L. Test Principle:

The diaDexus PLAC Test is based on turbidimetric immunoassay technology utilizing two Lp-PLA2 specific monoclonal antibodies (2C10 and 4B4) coated to latex microparticles. A set of $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ calibrators is used to plot a standard curve of absorbance (y-axis) versus $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ concentration in $\mathrm { n g / m L }$ (x-axis) from which the Lp-PLA2 concentration in the test sample can be determined. Two levels of controls are assayed to monitor performance within the clinical range of the assay. The concentration of $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ in each sample and control is interpolated from the standard curve using a spline curve fit with calibration curve fitting software.

# M. Performance Characteristics (if/when applicable):

The PLAC Test was validated on the Hitachi® 917.

1. Analytical performance:

a. Precision/Reproducibility:

Intra-assay, inter-assay and total precision was assessed according to CLSI EP5-A2 with three reagent lots. Two controls (143.9 and $4 4 9 . 5 \mathrm { n g / m L }$ and one serum $( 6 8 . 5 \mathrm { n g / m L } )$ sample were run in duplicates in 2 separate runs on the Hitachi 917 analyzer for 20 days. The results shown below met the sponsors acceptance criteria (intra-assay precision $C V { < } 8 \%$ and total precision $\mathrm { C V } { < } 1 0 \%$ ).

<table><tr><td rowspan=1 colspan=1>ReagentLot</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean Lp-PLA2Conc. (ng/mL)</td><td rowspan=1 colspan=1>Intra-assay%CV n=80</td><td rowspan=1 colspan=1>Inter-assay%CV n=20</td><td rowspan=1 colspan=1>Total%CVn=80</td></tr><tr><td rowspan=3 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>449</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=3 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>449</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=3 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.8</td></tr></table>

# b. Linearity/assay reportable range:

The recovery of reportable range was assessed according to CLSI EP6-A. Two high Lp-PA2 serum samples were mixed with low samples to product 11 concentrations/data points. The samples were assayed in duplicates with 3 lots on a single analyzer. The five level dilution series was conducted on a low serum sample. To further assess the lower end of the claimed assay range, the sponsor conducted an additional linearity study. Native human Lp-PLA2 was diluted with fetal bovine serum (used as a negative serum source) to the lowest level of detection. Percent recovery was determined and linear regression analysis was conducted. Additionally, the zero calibrator was titrated with an extremely high level of recombinant Lp-PLA2 up to 1500 $\mathrm { n g / m L }$ and dilutions were tested to asses the prozone or high dose hook effect. Three lots of reagents were evaluated over three separate runs on one analyzer. The results below met the sponsor’s acceptance criterion (percent recovery between 90 and $1 1 0 \%$ of the established mean and no hook effect below $1 5 0 0 ~ \mathrm { n g / m L } )$ ). The linear range is defined as ${ \mathrm { 7 } } { \mathrm { - } } 5 0 0 { \mathrm { ~ n g / m L } }$ .

<table><tr><td rowspan=2 colspan=1>Reagent Lot</td><td rowspan=2 colspan=1>HighSampleng/mL</td><td rowspan=2 colspan=1>LowSampleng/mL</td><td rowspan=2 colspan=1>Average%Recovery</td><td rowspan=1 colspan=3>Linear RegressionParameters</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=2 colspan=1>HumanSerum(lot 1)</td><td rowspan=1 colspan=1>483.4</td><td rowspan=1 colspan=1>109.9</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>-13.6</td><td rowspan=1 colspan=1>0.995</td></tr><tr><td rowspan=1 colspan=1>487.1</td><td rowspan=1 colspan=1>104.2</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.998</td></tr><tr><td rowspan=2 colspan=1>HumanSerum(lot 2)</td><td rowspan=1 colspan=1>432.6</td><td rowspan=1 colspan=1>94.7</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>0.998</td></tr><tr><td rowspan=1 colspan=1>461.8</td><td rowspan=1 colspan=1>89.7</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>-5.1</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=2 colspan=1>HumanSerum(lot 3)</td><td rowspan=1 colspan=1>460.2</td><td rowspan=1 colspan=1>98.3</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>15.8</td><td rowspan=1 colspan=1>0.994</td></tr><tr><td rowspan=1 colspan=1>472.3</td><td rowspan=1 colspan=1>95.8</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.999</td></tr><tr><td rowspan=1 colspan=1>HumanSerum</td><td rowspan=1 colspan=1>89.0</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>-3.3</td><td rowspan=1 colspan=1>0.992</td></tr><tr><td rowspan=1 colspan=1>HumanHigh,bovine low</td><td rowspan=1 colspan=1>438.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>-6.9</td><td rowspan=1 colspan=1>0.997</td></tr><tr><td rowspan=1 colspan=1>HumanHigh,bovine low</td><td rowspan=1 colspan=1>312.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>-6.9</td><td rowspan=1 colspan=1>0.997</td></tr><tr><td rowspan=1 colspan=1>HumanHigh,bovine low</td><td rowspan=1 colspan=1>213.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>-6.9</td><td rowspan=1 colspan=1>0.997</td></tr></table>

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

The purified recombinant Lp-PLA2 antigen is utilized as the analyte in the

PLAC test calibrators and controls. A master calibrator was prepared from purified primary stock solution of recombinant Lp-PLA2 that was quantitated by amino acid analysis. A master calibrator was prepared and the value was assigned using a panel of stored human serum samples that were characterized by multiple runs with the predicate device. The calibrators are manufactured to match the absorbance levels of the master calibrator at each calibration level (0, 50, 100, 250 and $5 0 0 ~ \mathrm { { n g / m L } }$ ). Controls are manufactured to a target value, but assigned the actual value range generated by multiple PLAC test runs. Quality control acceptance criteria are that the calibrators must quantitate replicates of the quality control panel serum samples within $+ / .$ - $10 \%$ of the established mean. The formulation used for both the calibrators and controls has been validated with the predicate device. The sponsor states a real-time stability of 16 months at 2 to $8 ^ { \circ } \mathrm { C }$ .

# d. Detection limit:

The sponsor conducted a Limit of Detection (LOD) and a Limit of Quantitation (LOQ) study. The detection limit was defined as the lowest concentration that is significantly different from zero. Calibrator 1 $\mathrm { ( 0 \ n g / m L ) }$ and Calibrator 2 $( 2 0 \mathrm { n g / m L } )$ were assay 20 times with three reagent lots in the same run. The mean of the zero calibrator plus 2 standard deviations was calculated as 4.5, 5.1 and $4 . 0 \mathrm { n g / m L }$ . The limit of quantitation was defined as the lowest analyte concentration where the $\%$ CV of precision is less than $20 \%$ . The $5 0 ~ \mathrm { n g / m L }$ calibrator was titrated down to zero with calibrator diluent in a series of 10 incremental levels. Each sample was assayed in replicates of 3 in 10 runs by three reagent lots on one analyzer. The study was also performed with a serum sample diluted with bovine serum to 10 levels ranging from $5 6 ~ \mathrm { n g / m L }$ down to $8 ~ \mathrm { n g / m L }$ . The limit of quantitation was estimated to be $7 \mathrm { n g / m L }$ in all three reagent lots using the calibrator series of samples and $1 1 ~ \mathrm { n g / m L }$ with the serum samples. The results from the above studies met the sponsor’s acceptance criteria for LOD and LOQ of less than $2 0 ~ \mathrm { n g / m L }$ . The sponsor’s limit of quantitation is estimated to be $7 . 0 \ : \mathrm { n g / m L }$ and limit of detection is $4 . 0 \mathrm { n g / m L }$ .

# e. Analytical specificity:

Five endogenous substances (hemoglobin, triglycerides, total cholesterol, bilirubin and human serum albumin) found in blood and exogenous substances (common and prescription drugs in the package insert) were evaluated for interference in the assay. Potential interfering substances were spiked with the interferent into four different serum samples with endogenous $\mathrm { L } { \mathsf { p } } { \mathsf { - P } } \mathrm { L A } _ { 2 }$ in the range of 160 to $4 7 0 ~ \mathrm { { n g / m L } }$ range. Defined amounts of the interferents at and exceeding a relevant physiological range were added to the serum samples, assayed in duplicate with three lots of reagents, and any resultant biases in analyte quantitation were reported. The highest levels were chosen according to CLSI Protocol EP7-A recommended high testing levels. Controls were prepared for each sample by spiking with the solvent used for each substance stock solution. Controls were matched to test samples for both volume and solvent concentration. Recoveries of test samples were calculated as result/matched control value $\textbf { x } 1 0 0 \%$ . The sponsor’s acceptance criterion was less than $10 \%$ error in detected Lp-PLA2 in the presence of the compound. There was no interference detected for any of the substances listed below.

<table><tr><td colspan="2">Endogenous</td><td colspan="2">Exogenous (OTC Drugs, etc.)</td></tr><tr><td>Potential Interferent</td><td>Test Concentration</td><td>Potential Interferent</td><td>Test Concentration</td></tr><tr><td>Bilirubin</td><td></td><td>Acetaminophen</td><td>1.66 μmol/L</td></tr><tr><td>Cholesterol</td><td>20 mg/dL 500 mg/dL</td><td>Aspirin</td><td>3330 μmol/L</td></tr><tr><td>Hemoglobin</td><td>10,000 mg/dL</td><td>Atorvastatin</td><td>20 μmol/L</td></tr><tr><td>Triglycerides</td><td>3000 mg/dL</td><td>Clopidogrel bisulfate</td><td>100 μmol/L</td></tr><tr><td>Total Albumin*</td><td>~6500 mg/dL</td><td>Diphenhydramine</td><td>19.6 μmol/L</td></tr><tr><td rowspan="4"></td><td></td><td>Fenofibrate</td><td>125 μmol/L</td></tr><tr><td></td><td>Lisinopril</td><td>0.74 μmol/L</td></tr><tr><td>* 2.5 g/dL albumin added to plasma pool</td><td>Metformin</td><td>310 μmol/L</td></tr><tr><td>of presumptively 4 g/dL albumin</td><td>Niacin</td><td>4800 μmol/L</td></tr><tr><td rowspan="4"></td><td></td><td>Pravastatin</td><td>100 μmol/L</td></tr><tr><td></td><td>Tolbutamide</td><td>2400 μmol/L</td></tr><tr><td></td><td>Vitamin C</td><td>227 μmol/L</td></tr><tr><td></td><td>Warfarin</td><td>64.9 μmol/L</td></tr></table>

f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

The current PLAC Test turbidimetric immunoassay method was compared to the PLAC Test ELISA microplate assay (k062234). The singlet point method comparison for the 794 unaltered stored human serum samples ranged from $< 7$ to $4 9 9 \mathrm { n g / m L }$ , obtained from banked study sets were within the sponsor’s linear range. The results are shown in the table below.

<table><tr><td rowspan=1 colspan=5>Regression Parameters</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Correl Coeff (r)</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>Results</td><td rowspan=1 colspan=1>0.92</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>-24.5</td><td rowspan=1 colspan=1>794</td></tr></table>

# b. Matrix comparison:

The sponsor conducted a recovery matrix and anticoagulant comparison study with the PLAC turbidimetric immunoassay. Ten plasma samples ranging from 79.4 to $2 0 1 . 3 ~ \mathrm { n g / m L }$ . The recovery ranges from $89 - 1 1 1 \%$ for EDTA plasma, $8 3 - 1 0 2 \%$ for Na heparin, $8 7 - 1 0 6 \%$ for Li heparin. Specific recovery percentages linear equations for the 10 samples are shown in the table below.

<table><tr><td rowspan="2">Sample</td><td rowspan="2">Serum</td><td rowspan="2">Plasma_K2 EDTA</td><td rowspan="2">%Rec Plasma to Serum</td><td rowspan="2">Na Heparin</td><td rowspan="2">%Rec Na Heparin to Serum</td><td rowspan="2">Lithium Heparin</td><td rowspan="2">%Rec Li Heparin to Serum</td></tr><tr><td></td></tr><tr><td>S01</td><td>180.0</td><td>182.8</td><td>102%</td><td>187.0</td><td>104%</td><td>188.0</td><td>104%</td></tr><tr><td>S02</td><td>112.9</td><td>101.7</td><td>90%</td><td>92.5</td><td>82%</td><td>103.8</td><td>92%</td></tr><tr><td>S03</td><td>165.6</td><td>170.3</td><td>103%</td><td>182.3</td><td>110%</td><td>180.7</td><td>109%</td></tr><tr><td>S04</td><td>155.3</td><td>173.5</td><td>112%</td><td>152.0</td><td>98%</td><td>163.1</td><td>105%</td></tr><tr><td>S05</td><td>91.9</td><td>95.5</td><td>104%</td><td>79.4</td><td>86%</td><td>82.7</td><td>90%</td></tr><tr><td>S06</td><td>197.4</td><td>201.3</td><td>102%</td><td>204.9</td><td>104%</td><td>211.5</td><td>107%</td></tr><tr><td>S07</td><td>70.3</td><td>79.4</td><td>113%</td><td>80.7</td><td>115%</td><td>81.7</td><td>116%</td></tr><tr><td>S08</td><td>157.1</td><td>156.6</td><td>100%</td><td>162.6</td><td>103%</td><td>166.4</td><td>106%</td></tr><tr><td>S09</td><td>161.2</td><td>142.2</td><td>88%</td><td>149.5</td><td>93%</td><td>140.8</td><td>87%</td></tr><tr><td>S10</td><td>170.3</td><td>166.5</td><td>98% 101%</td><td>172.2</td><td>101% 100%</td><td>176.9</td><td>104%</td></tr><tr><td colspan="7"></td><td colspan="2">102%</td></tr><tr><td colspan="7">y=.977x +4.10 y=1.09x-13.641 y=plasma x=serum y=Sodium Heparin x=serum</td><td colspan="2">y=1.08x-8.76 y=Lithium Heparin x=serum</td></tr></table>

Additionally, the sponsor conducted a matrix comparison study using 95 matched serum and EDTA samples that ranged from 132.1 to $4 0 2 ~ \mathrm { n g / m L }$ . The obtained recoveries ranged from 86.1 to $1 1 8 . 9 \%$ and the obtained linear regression equation was Y (serum) $=$ 0.986(EDTA) $+ 1 0 . 5 2$ .

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): See clinical data provided in k030477.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

The sponsor claims the same reference range as the initial device (k030477). The stored reference range samples were re-assayed by the PLAC test turbidimetric immunoassay to assess whether the results were statistically different from historical results. 155 plasma samples (61 females and 94 males) were assayed by the PLAC Test turbidimetric immunoassay in duplicate with one lot of reagents.

Additionally, the sponsor tested the samples against the ELISA PLAC test $\mathrm { k 0 5 0 5 2 3 }$ . The mean results for both tests were compared with the historical reference results using the Two Sample t-Test for assessment of statistical differences. The sponsor’s acceptance criterion is a Two-Sample t-Test analysis result of $\mathsf { p } \geq \ 0 . 0 5$ , which states no statistical difference. The results are presented in the table below.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Lp-PLA2 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>k072599Turbidimetricimmunoassay</td><td rowspan=1 colspan=1>k050523ELISA</td><td rowspan=1 colspan=1>k030477Historical Values</td></tr><tr><td rowspan=1 colspan=1>Lp-PLA2 Percentile</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>172</td><td rowspan=1 colspan=1>195</td><td rowspan=1 colspan=1>157</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>212</td><td rowspan=1 colspan=1>229.7</td><td rowspan=1 colspan=1>201.7</td></tr><tr><td rowspan=1 colspan=1>50 (Median)</td><td rowspan=1 colspan=1>245.4</td><td rowspan=1 colspan=1>261</td><td rowspan=1 colspan=1>234.9</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>295</td><td rowspan=1 colspan=1>294</td><td rowspan=1 colspan=1>274</td></tr><tr><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>359</td><td rowspan=1 colspan=1>358</td><td rowspan=1 colspan=1>349</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>253</td><td rowspan=1 colspan=1>265</td><td rowspan=1 colspan=1>241</td></tr><tr><td rowspan=1 colspan=1>95% CI of Mean</td><td rowspan=1 colspan=1>244-263</td><td rowspan=1 colspan=1>256273</td><td rowspan=1 colspan=1>232250</td></tr><tr><td rowspan=1 colspan=1>NP value turbidimetricvs. historicalP value turbidimetricvs. ELISA</td><td rowspan=1 colspan=1>1550.08420.0539</td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>155</td></tr></table>

The sponsor has chosen to use the previously obtained expected values from k030477 that are stated below.

“ Samples from apparently healthy males $\scriptstyle ( \mathrm { n } = 2 5 1$ ) and apparently healthy females $\scriptstyle ( \mathrm { n } = 1 7 4 )$ , in the clinically relevant age range of 40 to 70 years, were evaluated with the diaDexus PLAC Test. The reference population was represented by the following ethnic backgrounds: African-American $\mathrm { n } { = } 2 6$ , Caucasian $\scriptstyle \mathrm { n = 3 9 0 }$ , Hispanic $\mathrm { n } { = } 8$ and not specified $\mathrm { \tt n } { = } 1$ . The distributions of Lp- $\mathrm { P L A } _ { 2 }$ values across the entire population and divided by gender appear in the following table:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Lp-PLA ng/mL</td></tr><tr><td rowspan=1 colspan=1>Percentile</td><td rowspan=1 colspan=1>All (n=425)</td><td rowspan=1 colspan=1>Females (n=174)</td><td rowspan=1 colspan=1>Males (n=251)</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>131</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>174</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>179</td></tr><tr><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>201</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>205</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>228</td><td rowspan=1 colspan=1>244</td></tr><tr><td rowspan=1 colspan=1>67</td><td rowspan=1 colspan=1>262</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>268</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>289</td><td rowspan=1 colspan=1>285</td><td rowspan=1 colspan=1>293</td></tr><tr><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>369</td><td rowspan=1 colspan=1>342</td><td rowspan=1 colspan=1>376</td></tr></table>

The reference interval calculated from the samples (central $9 0 \%$ ) was found to be $1 2 0 { - } 3 4 2 ~ \mathrm { n g / m L }$ for females and $1 3 1 { - } 3 7 6 ~ \mathrm { n g / m L }$ for males.”

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.